• TRAX share price: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • Price change

    The price of TRAX shares has increased $2.47 since the market last closed. This is a 5.44% rise.

  • Closed at $47.90.

    The stock has since dropped $0.90 in after-hours trading.

Key terms

About TRAX

First Tracks Biotherapeutics, Inc. engages in the research and development of immunology therapeutics for autoimmune and inflammatory diseases. It focuses on clinical-stage programs for rosnilimab, ANB033 and ANB101. The company is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
  • Market cap: $2.01B

    A market capitalization between $2 billion and $10 billion places TRAX in the mid-capitalization category.

Key terms

Smart score

Latest TRAX news

Nov 05, 2026 9:30am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX) and Medline (MDLN) by TipRanks Nov 05, 2026 7:35am ET First Tracks Biotherapeutics price target lowered to $57 from $60 at Canaccord by TipRanks Nov 04, 2026 9:02am ET Wedbush Reaffirms Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Nov 04, 2026 8:59am ET First Tracks Biotherapeutics Inc (TRAX) Receives a Buy from Wells Fargo by TipRanks Nov 04, 2026 8:40am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), Douglas Emmett (DEI) and Mosaic Co (MOS) by TipRanks Nov 04, 2026 8:32am ET Analysts Are Bullish on Top NA Stocks: First Tracks Biotherapeutics Inc (TRAX), Septerna, Inc. (SEPN) by TipRanks Nov 04, 2026 7:51am ET First Tracks Biotherapeutics price target raised to $110 from $100 at Guggenheim by TipRanks Nov 04, 2026 4:01am ET Analysts Offer Insights on NA Companies: Eaglerock Land LLC Class A (EROK), First Tracks Biotherapeutics Inc (TRAX) and Medline (MDLN) by TipRanks Nov 04, 2026 4:00am ET Barclays Keeps Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Nov 03, 2026 5:00pm ET First Tracks Biotherapeutics reports Q3 EPS (88c), consensus (89c) by TipRanks Oct 26, 2026 7:40am ET First Tracks Biotherapeutics registers to sell 6.1M shares of common for holders by TipRanks Oct 20, 2026 7:30am ET Analysts Are Bullish on Top NA Stocks: Teamshares (TMS), First Tracks Biotherapeutics Inc (TRAX) by TipRanks Oct 16, 2026 9:35am ET First Tracks Biotherapeutics Inc (TRAX) Receives a Rating Update from a Top Analyst by TipRanks Oct 15, 2026 8:15am ET First Tracks Biotherapeutics announces $200M private placement by TipRanks Oct 13, 2026 9:26am ET First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from Wedbush by TipRanks Oct 13, 2026 9:05am ET TRAX: Buy Rating Backed by Strong ANB033 Phase 1b Celiac Data and Attractive Risk-Reward Upside by TipRanks Oct 13, 2026 8:36am ET First Tracks Biotherapeutics price target raised to $70 from $65 at Evercore ISI by TipRanks Oct 13, 2026 7:35am ET Analyst Raises First Tracks Biotherapeutics Price Target to $60 on Strong ANB033 Clinical Results and Expanded Pipeline by TipRanks Oct 13, 2026 7:20am ET Analysts Offer Insights on NA Companies: First Tracks Biotherapeutics Inc (TRAX), Klarna Group Plc (KLAR) and Factset Research (FDS) by TipRanks Oct 13, 2026 7:05am ET First Tracks Biotherapeutics price target raised to $60 from $50 at Canaccord by TipRanks Oct 13, 2026 5:16am ET Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX) by TipRanks Oct 12, 2026 5:40pm ET First Tracks Biotherapeutics price target raised to $70 from $62 at Wells Fargo by TipRanks Oct 12, 2026 12:01pm ET Midday Fly By: Amazon in talks to buy AI startup Decart, IonQ to acquire Elisity by TipRanks Oct 12, 2026 7:20am ET First Tracks Biotherapeutics reports results from Cohort 1 of ANB033 trial by TipRanks Oct 12, 2026 5:30am ET Analysts Offer Insights on NA Companies: American Integrity Insurance Group, Inc. (AII) and First Tracks Biotherapeutics Inc (TRAX) by TipRanks Oct 09, 2026 7:35am ET Edward Nash Reiterates Buy on First Tracks Biotherapeutics, Maintains $50 Price Target Amid Growing Confidence in ANB033 Program by TipRanks Oct 09, 2026 6:05am ET First Tracks Biotherapeutics price target raised to $62 from $55 at Wells Fargo by TipRanks Oct 09, 2026 5:55am ET Wells Fargo Keeps Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX) by TipRanks Oct 09, 2026 5:30am ET Analysts Conflicted on These NA Names: Amrize Ltd (AMRZ) and First Tracks Biotherapeutics Inc (TRAX) by TipRanks Sep 30, 2026 6:55am ET First Tracks Biotherapeutics initiated with a Buy at Canaccord by TipRanks Sep 30, 2026 5:20am ET First Tracks Biotherapeutics initiated with a Buy at Canaccord by TipRanks
Nov 03, 2026 4:15pm ET First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update by GlobeNewswire Nov 03, 2026 4:15pm ET First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences by GlobeNewswire Oct 15, 2026 8:00am ET First Tracks Biotherapeutics Announces $200 Million Private Placement by GlobeNewswire Oct 12, 2026 7:00am ET First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease by GlobeNewswire Oct 11, 2026 4:00pm ET First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026 by GlobeNewswire Aug 26, 2026 4:15pm ET First Tracks Biotherapeutics Announces Participation in September Investor Conferences by GlobeNewswire Aug 12, 2026 4:15pm ET First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update by GlobeNewswire

TRAX Financials

1-year income & revenue

  • TRAX total_revenue: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • TRAX net income: currently unavailable. Sorry, we currently don't have enough data to create an insight.

  • TRAX earnings per share: currently unavailable. Sorry, we currently don't have enough data to create an insight.

Key terms

TRAX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TRAX Competitors

$ Market capP/E ratio$ Price1d change52-week range
  • How competitors are chosen

    TRAX's competitors are included in the Health Technology sector and Biotechnology group

  • Market cap: $2.01B

    A market capitalization between $2 billion and $10 billion places TRAX in the mid-capitalization category.

Key terms

Latest investing news